| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| cabozantinib | vascular endothelial growth factor receptor 2 | small molecule | Successful target | TTD , drugbank , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Thyroid carcinoma[MeSHID:D013964] Medulla Oblongata[MeSHID:D008526] Liver carcinoma[MeSHID:D006528] Adrenal Medulla[MeSHID:D000313] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of ovary[MeSHID:D010051] |
0.27 | approved,investigational | antagonist,inhibitor |
| cabozantinib | vascular endothelial growth factor receptor 2 | small molecule | Successful target | TTD , drugbank , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Thyroid carcinoma[MeSHID:D013964] Medulla Oblongata[MeSHID:D008526] Liver carcinoma[MeSHID:D006528] Adrenal Medulla[MeSHID:D000313] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of ovary[MeSHID:D010051] |
0.27 | approved,investigational | antagonist |
| cabozantinib | proto-oncogene c-met | NA | Successful target | TTD , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Thyroid carcinoma[MeSHID:D013964] Medulla Oblongata[MeSHID:D008526] Liver carcinoma[MeSHID:D006528] Adrenal Medulla[MeSHID:D000313] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of ovary[MeSHID:D010051] |
0.75 | approved | inhibitor |
| cabozantinib | hepatocyte growth factor receptor | small molecule | NA | drugbank , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Thyroid carcinoma[MeSHID:D013964] Medulla Oblongata[MeSHID:D008526] Liver carcinoma[MeSHID:D006528] Adrenal Medulla[MeSHID:D000313] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of ovary[MeSHID:D010051] |
0.75 | approved,investigational | antagonist |
| cabozantinib | proto-oncogene c-met | NA | Successful target | TTD , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Thyroid carcinoma[MeSHID:D013964] Medulla Oblongata[MeSHID:D008526] Liver carcinoma[MeSHID:D006528] Adrenal Medulla[MeSHID:D000313] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of ovary[MeSHID:D010051] |
0.75 | approved | unknown |
| cabozantinib | hepatocyte growth factor receptor | small molecule | NA | drugbank , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Thyroid carcinoma[MeSHID:D013964] Medulla Oblongata[MeSHID:D008526] Liver carcinoma[MeSHID:D006528] Adrenal Medulla[MeSHID:D000313] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of ovary[MeSHID:D010051] |
0.75 | approved,investigational | antagonist,inhibitor |
| cabozantinib | proto-oncogene tyrosine-protein kinase receptor ret | small molecule | NA | drugbank , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Thyroid carcinoma[MeSHID:D013964] Medulla Oblongata[MeSHID:D008526] Liver carcinoma[MeSHID:D006528] Adrenal Medulla[MeSHID:D000313] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of ovary[MeSHID:D010051] |
1.36 | approved,investigational | antagonist,inhibitor |
| cabozantinib | proto-oncogene tyrosine-protein kinase receptor ret | small molecule | NA | drugbank , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Thyroid carcinoma[MeSHID:D013964] Medulla Oblongata[MeSHID:D008526] Liver carcinoma[MeSHID:D006528] Adrenal Medulla[MeSHID:D000313] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of ovary[MeSHID:D010051] |
1.36 | approved,investigational | antagonist |
| click here to return to the previous page | ||||||||